Zunveyl (benzgalantamine)
Indications for Prior Authorization
Zunveyl (benzgalantamine)
-
For diagnosis of Mild to Moderate Dementia in Alzheimer’s
Indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.
Criteria
Zunveyl
Step Therapy
Length of Approval: 12 Month(s)
- Requested drug is being used for a Food and Drug Administration (FDA)-approved indication AND
- Trial and failure (of a minimum 30-day supply), contraindication, or intolerance to TWO of the following:
- generic galantamine
- generic rivastigmine
- generic donepezil
P & T Revisions
1970-01-01
References
- Zunveyl Prescribing Information. Alpha Cognition, Inc. Grapevine, TX. July 2024.
- Liu, A., and Kansteiner, F. Game on: Lilly's Alzheimer's drug Kisunla, a challenger to Biogen and Eisai's Leqembi, gains full FDA nod. Available at: https://www.fiercepharma.com/pharma/game-lillys-alzheimers-drug-kisunla-challenger-biogen-and-eisais-leqembi-gains-full-fda-nod. Accessed March 18, 2025.
- Ellis, R., and Landmaid, S. Cholinesterase Inhibitors. Available at: https://www.webmd.com/alzheimers/cholinesterase-inhibitors-alzheimers. Accessed March 18, 2025.
- Hansen, R., Gartlehner, G., Webb, A., et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Available at: https://www.tandfonline.com/doi/full/10.2147/cia.S12159936. Accessed March 18, 2025.
- Practice Guideline for the Treatment of Patients With Alzheimer’s Disease and Other Dementias. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/alzheimers.pdf. Accessed March 18, 2025.
End Notes
- Unlike Zunveyl, which targets the symptoms of Alzheimer’s disease, Leqembi and Kisunla attempt to slow the progression of the disease by purging beta-amyloid proteins from the brain. Beta amyloids can build up over time, and they are believed to clog and slow the network of cells responsible for memory and thinking [2]
HEALTHY LIVING